fda drug shortage list semaglutide US judge upholds FDA's removal of Ozempic, Wegovy from compounded semaglutide deadline As of

What the FDA Requires in the BLA Efficacy Data: TRIUMPH-4: 28.7% weight loss Complete TRIUMPH-1: 28.3% weight loss Complete TRIUMPH-2: 20.8% weight loss (obesity + diabetes) Complete TRIUMPH-3: 22.6% weight loss (obesity + cardiovascular disease) Complete, MACE data not statistically significant Safety Data: Side effect profile across all four populations Short-term and medium-term adverse events, including the dysesthesia signal (up to 20.9% at 12mg) Drug interactions, especially with diabetes medications Manufacturing Data: Scale-up capability for millions of doses per month Quality control and stability data Cold chain distribution logistics Realistic Approval Scenarios With the BLA filing point now expected (Q1 2027), the remaining uncertainty is largely in the FDA review itself not in whether or when Lilly files

C., Mlck, A., Nielsen, H

Link Winblad, B

Clinical Update 4/26/2024 Alpha-Lipoic Acid for Nerve Pain

MCO-level coverage in the 15 highest-population states State Medicaid programs operate as a fee-for-service (FFS) component plus contracted managed-care organizations (MCOs)